Access and Delivery of Essential Medicines

2007 Archive

A .mov player such as Quicktime is required to watch videos after 2009.

Realplayer is required to watch videos older than 2009. Free Realplayer 11 is located at: download.com and real.com. Realplayer 10.5 is located at download.com.

Addressing the Challenges of HIV/AIDS and TB in the Developing World

Nick Hellman, MD, Bill & Melinda Gates Foundation
Feb 2007
 
Watch Video

A New Era of Hope for the World's Most Neglected Diseases

Gavin Yamey, MD MRCP, Senior Editor PLoS Medicine, Consulting Editor PLoS Neglected Diseases
Oct 2007

Gavin Yamey kicks off another year of ADEM by defining what Neglected Tropical Diseases are and highlights their impact on global health.

Watch Video - <unavailable; see Feb 2006 video>

 

Bill Gates' Other Business:Designing Shrewd Incentives for Neglected Disease Research

Stephen Maurer, JD; Director, Goldman School Project on Information Technology and Homeland Security, UC Berkeley
Oct 2007
Stephen Maurer's research interests include designing better institutions and incentives for neglected disease research, academic/industry relations, patent law, antitrust issues, open source biology, database policy and homeland security. Maurer has practiced high technology and intellectual property litigation at leading law firms in Arizona and California. He is currently Director of the Goldman School Project on Information Technology and Homeland Security (ITHS), which serves as a focal point for the School's science, innovation, and technology initiatives.
Watch Video

 

Can We Control the Global HIV/AIDS Epidemic?

Nick Hellman, MD; Program Leader, HIV/AIDS Program, The Bill and Melinda Gates Foundation
Oct 2007

Dr. Hellmann is the Program Leader of the HIV/AIDS Program at the Bill and Melinda Gates Foundation. In this capacity, he is responsible for strategy, research, program and policies related to HIV/AIDS for the Foundation.

Dr. Hellmann received his M.D. degree from the University of Kentucky in 1982, and completed his Internal Medicine Residency and Infectious Diseases Fellowship training at UCSF. After completion of his fellowship training in 1988, Dr. Hellmann was an Assistant Professor in the Internal Medicine/Infectious Diseases Division at UCSF and was later an Infectious Diseases Consultant in a private medical practice. While on the Department of Medicine Faculty at UCSF, Dr Hellmann lived and worked in Uganda, East Africa from 1989-1991 where he conducted research to identify HIV risk factors and develop effective intervention strategies to reduce heterosexual HIV transmission. Prior to joining the Foundation, Dr. Hellmann worked in the pharmaceutical and biotechnology sector for 12 years on the development of antimicrobial drugs and molecular diagnostic technologies for many infectious diseases and other health conditions. Most recently he held positions as the Chief Medical Officer at Roche Molecular Systems (Pleasanton, CA), the global leader in the development of nucleic acid-based diagnostic tests for individualized clinical management of human diseases, and Vice President of Clinical Research at ViroLogic, a leading company in the development of therapy guidance technologies related to evaluation and management of drug resistance in serious viral infections, such as HIV and hepatitis. Prior to these roles, Dr. Hellmann held positions at Gilead Sciences, Genentech, and Bristol-Myers Squibb, where he directed clinical research activities related to the development of novel antiviral and antimicrobial drugs, especially drugs for treatment of HIV infection.

Watch Video

 

Drug access for developing nations: finding a politically plausible approach

Considerations in University Technology Transfer and Drug Access for Developing Nations

Kirsten Leute, MBA; Senior Licensing Associate, Office of Technology Licensing, Stanford University
John Barton, JD; Stanford Law School

Oct 2007

Kirsten Leute received a B.A. in Biological Sciences from Wellesley College and an M.B.A. from Santa Clara University. She previously worked as an R&D Chemist and QC Analyst at Boehringer-Mannheim Diagnostics and as a Technology Manager at Deutsches Krebsforschungszentrum. Her responsibilities with the Office of Technology Licensing include biotechnology and physical sciences. She has written about the licensing and patenting of university-based biotechnology discoveries.

John Barton received a J.D. from Stanford Law School and has devoted his academic career to the examination of questions at the intersection of science and the law. A fellow of the American Association for the Advancement of Science, an honor rarely bestowed upon a law professor, Professor Barton has focused his scholarship on international law concerns ranging from national defense to issues surrounding the distribution of intellectual property across the developed and undeveloped world. His current work involves the study of the transfer of technologies, including vaccines and steel, between scientifically sophisticated and developing nations, and the development of a political theory of international organization and globalization. Professor Barton has chaired or been a member of more than a dozen academic and international advisory commissions, most recently heading up the International Commission on Intellectual Property Rights. Before joining the Stanford Law School faculty in 1969, Professor Barton was an engineer with Sylvania Electronic Defense Laboratories.

Watch Video

 

Breaking down barriers... building solutions

Chris Earl, PhD; President and CEO, BIO Ventures for Global Health
Nov 2007
BIO Ventures for Global Health: http://www.bvgh.org/default.asp
Watch Video

 

Across the Spectrum: From Molecular Virology and Pathogenesis to Clinical and Epidemiological Studies of Dengue

Eva Harris, PhD, associate professor of infectious diseases at UC Berkeley and president of the Sustainable Sciences Institute
Dec 2007

Eva Harris is Associate Professor of Infectious Diseases, Director of the Center for Global Public Health, and Associate Dean for Research in the School of Public Health at UC Berkeley. Dr. Harris graduated magna cum laude from Harvard University in Biochemical Sciences before earning her Ph.D. in molecular and cell biology in the laboratory of Dr. Jeremy Thorner at UC Berkeley in 1993. She conducted her post-doctoral work at UCSF and joined the faculty at UC Berkeley in 1998. Dr. Harris has received many awards in recognition of her superb laboratory and public health skills including a prestigious MacArthur Fellowship (aka "Genius Award") from the MacArthur Foundation in 1997. Using the funds from the Genius Award, Dr. Harris founded the Sustainable Sciences Institute (SSI), a non-profit organization based in San Francisco. SSI strives to develop scientific research capacity in countries with pressing public health problems by helping scientists in these areas gain access to the resources needed to address local problems related to infectious diseases.

Dr. Harris focuses her efforts on combating diseases that primarily afflict people in developing nations. For example, she hopes that her research on the molecular biology of the dengue virus will eventually lead to a vaccine or antiviral therapies, while her work in dengue-endemic countries like Nicaragua will lead to better control of the mosquito that transmits dengue. In 1998, Harris published the book, "A Low Cost Approach to PCR: Appropriate Transfer of Biomolecular Techniques," which strips an expensive DNA analysis technique down to its principles so that it becomes practical and inexpensive for use by people in developing nations.

The following websites may be of interest:
Bio page at Berkeley: http://www.berkeley.edu/news/extras/experts/harris.html
Sustainable Sciences Institute: http://www.ssilink.org/

Watch Video

 

 

Is There Any Hope for Tackling the World’s Most Neglected Diseases?

Ahvie Herskowitz, MD; Senior Vice President, Chief Medical Officer and Co-Founder, Institute for OneWorld Health
Dec 2007

iOWH is currently developing medicines for visceral leishmaniasis, diarrheal diseases, malaria and Chagas disease. Last year iOWH gained FDA approval for paromomycin, an off patent antibiotic they have been developing as a new cure for visceral leishmaniasis. From the iOWH website: "iOWH challenges the assumption that pharmaceutical research and development is too expensive to create the new medicines that the developing world desperately needs. By partnering and collaborating with industry and researchers, by securing donated intellectual property, and by utilizing the scientific and manufacturing capacity of the developing world, OneWorld Health can deliver affordable, effective and appropriate new medicines where they are needed most.

Dr Herskowitz provides senior executive leadership to the Institute for OneWorld Health. He has extensive experience performing large-scale multinational phase II and III clinical trials. Prior to co-founding iOWH Ahvie directed all multinational clinical trials at a cardiovascular research institute, including all epidemiologic and outcome studies and registries. Dr. Herskowitz has been trained in the fields of cardiology, immunology and pathology. A former Associate Professor of Medicine, Immunology and Molecular Microbiology at Johns Hopkins, Dr. Herskowitz is a Clinical Professor in the Department of Medicine at University of California, San Francisco. He received his MD from Albert Einstein College of Medicine.

Watch Video

 

Footer Links: